Rx License-Rx

24-10698-aiNCS

LNP-Enabled Intracellular Delivery of Recombinant bioPROTACs

Recombinant fusion bioPROTACs are combined with cationic delivery agents and lipid formulations to enable cytosolic entry and on-demand intracellular degradation of target proteins. Problem: Many endogenous proteins remain difficult to modulate with conventional drugs due to limited opportunities for effective small-molecule binding. Protein-degradation strategies can expand what is addressable, but recombinant degraders still face practical intracellular delivery barriers. Common delivery approaches can be complex, cytotoxic, or introduce delays before degradation occurs. Solution: This technology provides recombinant fusion proteins and compositions designed to promote cytoplasmic delivery and targeted intracellular protein degradation. The fusion proteins combine an E3 ubiquitin ligase domain with a small protein binding scaffold that targets a selected intracellular protein for degradation. The compositions include a cationic...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Liver disease

Modality: Small Molecule

Focus tags: Oncology, Immunology, Inflammation, Neurology, Cardiometabolic

Technology tags: Small Molecule, Biologic, Drug Delivery, Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: PCT Filed WO2025184400A1

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Liver disease. Public description: Recombinant fusion bioPROTACs are combined with cationic delivery agents and lipid formulations to enable cytosolic entry and on-demand intracellular degradation of target proteins. Problem: Many endogenous proteins remain difficult to.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Liver disease

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.